Through Prism Diagnostics (PrismDx), we predict if a patient will respond to a targeted drug or not. By applying the unprecedented amounts of data generated from PrismDx to our protein-interaction map, the Prism Intelligence (PrismIx) platform will improve our understanding of diseases, and drive Prism Rx (Therapeutics) to help pharmaceutical companies create new treatments for patients who do not respond to drugs currently available on the market, moving our entire field toward the ultimate goal — effective treatment for every patient from day one.
PrismRA is a simple blood test in development that predicts response to anti-TNF therapies for patients with Rheumatoid Arthritis, so they can be prescribed treatments that are more likely to work for them. If PrismRA was ordered before prescribing 100% of all anti-TNF drugs in the United States, it would double adequate drug response rates for RA patients from 35% up to 67% while potentially saving over $4.7 billion annually in wasted prescription costs.
PrismUC is a simple blood test in development that identifies Ulcerative Colitis patients who will not respond to anti-TNF therapies, so they can be prescribed therapies that will more likely work for them. By bringing precision medicine to patients suffering from UC, $3.9 billion could be saved annually in ineffective prescriptions.5,6,7
By combining the data collected from PrismDx with our PrismIx platform, we explore unknown human biology to understand what makes a patient a “responder” or “non-responder” to a particular therapy, and therefore able to improve patient stratification.
Using this approach, we can rescue drugs that have already proven to be safe and only give them to those who will most likely respond, therefore improving response rates to these drugs and helping more patients reach treatment goals.
Our first targets are being developed for ulcerative colitis to help the patients who do not respond to currently available drugs.